Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DoriDuo is a fixed-dose combination lozenge developed by MEDICE Arzneimittel Puetter for the symptomatic treatment of acute pharyngitis (sore throat) in adults. It contains 25 mg of ibuprofen and 1.1 mg of levomenthol. Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) that provides analgesic and anti-inflammatory effects by inhibiting the enzymes cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing the production of pro-inflammatory prostaglandins in the pharyngeal mucosa. Levomenthol acts as an agonist at the TRPM8 (transient receptor potential melastatin 8) cold receptors, producing a cooling sensation and providing mild local anesthetic properties to soothe irritation. This combination is intended for short-term use to manage pain and swelling associated with throat infections, offering both systemic anti-inflammatory action and local sensory relief.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ibuprofen + levomenthol.